Clinical trial
Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and…
NCT00303329 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00303329 |
|---|---|
| Title | Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients |
| Official title | Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Other Patients With Rare Chronic Anemia and Transfusional Iron Overload |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anemia, Hemosiderosis |
| Intervention type | Drug |
| Interventions | Deferasirox |
| Enrollment | 184 |
| Start date | Mar 1, 2004 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Mar 16, 2006 |
| Last update posted | May 9, 2011 |
| Countries | Belgium, Canada, France, Germany, Italy, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: